Phenotypes associated with this allele

• Allele Symbol: Dmtf1⁺
• Allele Name: wild type
• Allele ID: MGI:2438057
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Dmtf1^tm1Cjs/Dmtf1^+	involves: 129/Sv * C57BL/6	MGI:3692581
cx2	Dmtf1^tm1Cjs/Dmtf1^+ Tg(IghMyc)22Bri/0	involves: 129/Sv * C57BL * C57BL/6 * SJL	MGI:3692583
cx3	Dmtf1^tm1Cjs/Dmtf1^+ Kras^tm2Tyj/Kras^+	involves: 129S2/SvPas * C57BL/6	MGI:3770615
cx4	Dmtf1^tm1Cjs/Dmtf1^+ Kras^tm3Tyj/Kras^+	involves: 129S4/SvJae * C57BL/6	MGI:3770617

Genotype
MGI:3692581

ht1

• Allelic Composition: Dmtf1^tm1Cjs/Dmtf1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased tumor incidence ( J:63444 , J:72617 )

• low but elevated tumor incidence in the first year (J:63444)

• wide variety of tumor types (J:63444)

• spontaneous lethal tumors develop with a high level of frequency in the second year of life, mean latency 83 weeks (J:72617)

increased incidence of induced tumors ( J:63444 )

• very susceptible to tumor induction by either ionizing radiation or dimethylbenzanthracene

Genotype
MGI:3692583

cx2

• Allelic Composition: Dmtf1^tm1Cjs/Dmtf1⁺; Tg(IghMyc)22Bri/0
• Genetic Background: involves: 129/Sv * C57BL * C57BL/6 * SJL

neoplasm

decreased tumor latency ( J:72617 )

• accelerated tumor formation as compared to mice carrying only Tg(IghMyc)22Bri

Genotype
MGI:3770615

cx3

• Allelic Composition: Dmtf1^tm1Cjs/Dmtf1⁺; Kras^tm2Tyj/Kras⁺
• Genetic Background: involves: 129S2/SvPas * C57BL/6

mortality/aging

premature death ( J:126002 )

• mean survival time of double mutants is 41 weeks compared to 55 weeks for Kras^LA+/-, Dmtf1-sufficient mice

neoplasm

increased cholangiocarcinoma incidence ( J:126002 )

• one case of cholangiocarcinoma was observed

increased T cell derived lymphoma incidence ( J:126002 )

• ~30% of mice develop thymic lymphomas

increased skin papilloma incidence ( J:126002 )

• 20-30% of animals develop tail papillomas

abnormal metastatic potential ( J:126002 )

• <5% of animals show distant metastases (liver/intr-abdominal or leg) of lung tumors, while no metastases are observed in Kras^LA+/-, Dmtf1-sufficient mice

increased neurofibroma incidence ( J:126002 )

• one case of neurofibroma was observed

increased osteosarcoma incidence ( J:126002 )

• one case of osteosarcoma was observed

increased lung tumor incidence ( J:126002 )

• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion

increased lung adenoma incidence ( J:126002 )

• all mice develop lung adenomas or lung adenocarcinomas

increased lung adenocarcinoma incidence ( J:126002 )

• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in Kras^LA+/- single mutants

• number of tumor nodules increase as animals become sick, with trend to increased nodule size

decreased tumor latency ( J:126002 )

• tumorigenesis is accelerated relative to heterozygous Kras, wild-type Dmtf1 mice

integument

increased skin papilloma incidence ( J:126002 )

• 20-30% of animals develop tail papillomas

endocrine/exocrine glands

increased cholangiocarcinoma incidence ( J:126002 )

• one case of cholangiocarcinoma was observed

increased T cell derived lymphoma incidence ( J:126002 )

• ~30% of mice develop thymic lymphomas

liver/biliary system

increased cholangiocarcinoma incidence ( J:126002 )

• one case of cholangiocarcinoma was observed

skeleton

increased osteosarcoma incidence ( J:126002 )

• one case of osteosarcoma was observed

nervous system

increased neurofibroma incidence ( J:126002 )

• one case of neurofibroma was observed

respiratory system

increased lung tumor incidence ( J:126002 )

• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion

increased lung adenoma incidence ( J:126002 )

• all mice develop lung adenomas or lung adenocarcinomas

increased lung adenocarcinoma incidence ( J:126002 )

• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in Kras^LA+/- single mutants

• number of tumor nodules increase as animals become sick, with trend to increased nodule size

immune system

increased T cell derived lymphoma incidence ( J:126002 )

• ~30% of mice develop thymic lymphomas

hematopoietic system

increased T cell derived lymphoma incidence ( J:126002 )

• ~30% of mice develop thymic lymphomas

Genotype
MGI:3770617

cx4

• Allelic Composition: Dmtf1^tm1Cjs/Dmtf1⁺; Kras^tm3Tyj/Kras⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:126002 )

• mean survival time of double mutants is 21 weeks compared to 35 weeks for Kras^+/-, Dmtf1-sufficient mice

neoplasm

increased T cell derived lymphoma incidence ( J:126002 )

• ~35% of mice develop thymic lymphomas

increased skin papilloma incidence ( J:126002 )

• 10-20% of animals develop tail papillomas

abnormal metastatic potential ( J:126002 )

• <5% of animals show distant metastases (liver/intr-abdominal or leg) of lung tumors, while no metastases are observed in Kras^LA+/-, Dmtf1-sufficient mice

increased lung tumor incidence ( J:126002 )

• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion

increased lung adenoma incidence ( J:126002 )

• all mice develop lung adenomas or lung adenocarcinomas

increased lung adenocarcinoma incidence ( J:126002 )

• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in Kras^LA+/- single mutants

• number of tumor nodules increase as animals become sick, with trend to increased nodule size

decreased tumor latency ( J:126002 )

• tumorigenesis is accelerated relative to heterozygous Kras, wild-type Dmtf1 mice

integument

increased skin papilloma incidence ( J:126002 )

• 10-20% of animals develop tail papillomas

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:126002 )

• ~35% of mice develop thymic lymphomas

respiratory system

increased lung tumor incidence ( J:126002 )

• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion

increased lung adenoma incidence ( J:126002 )

• all mice develop lung adenomas or lung adenocarcinomas

increased lung adenocarcinoma incidence ( J:126002 )

• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in Kras^LA+/- single mutants

• number of tumor nodules increase as animals become sick, with trend to increased nodule size

hematopoietic system

increased T cell derived lymphoma incidence ( J:126002 )

• ~35% of mice develop thymic lymphomas

immune system

increased T cell derived lymphoma incidence ( J:126002 )

• ~35% of mice develop thymic lymphomas